Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced it will present a Trial in Progress on its Phase 2/3 study of intravenous amisulpride for preventing postoperative nausea and vomiting in pediatric patients at the SAMBA 2024 Annual Meeting. The study targets patients from birth to 17 years and aims to share preliminary results in the second half of 2025.
April 30, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eagle Pharmaceuticals is presenting its ongoing study on amisulpride for pediatric PONV at SAMBA 2024, with results expected in 2025.
The announcement of Eagle Pharmaceuticals' presentation at a significant medical conference can positively impact investor perception, highlighting the company's ongoing research and development efforts. The focus on pediatric PONV prevention positions EGRX in a niche yet critical area of postoperative care, potentially opening new market opportunities upon successful trial outcomes. The anticipation of preliminary results in 2025 may also sustain investor interest and speculation on the company's future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100